Related Experiment Video

Updated: Jul 2, 2025

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function
09:20

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function

Published on: May 4, 2021

3.6K

The novel adiponectin receptor agonist APN5N alleviates sensitive skin by upregulating adiponectin expression

Eun Ju Kim1, Qing-Ling Quan1, Soo Ick Cho1

  • 1Department of Dermatology, Seoul National University College of Medicine, Korea; Laboratory of Cutaneous Aging Research, Biomedical Research Institute, Seoul National University Hospital, Korea; Institute of Human-Environment Interface Biology, Seoul National University, Korea.

Journal of Dermatological Science
|February 17, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Adipocyte-Specific ATAC-Seq with Adipose Tissues Using Fluorescence-Activated Nucleus Sorting11:11

Adipocyte-Specific ATAC-Seq with Adipose Tissues Using Fluorescence-Activated Nucleus Sorting

Published on: March 17, 2023

2.3K
Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research09:42

Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research

Published on: April 19, 2017

7.5K

Related Concept Videos

Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
322